US 7,557,193 B2
	Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
Dominique Lombardo, Marseille (France); Eric Mas, Marseille (France); Marie-Odile Sadoulet, Marseille (France); Laurence Panicot-Dubois, Canohes (France); and Jean-Paul Bernard, Marseille (France)
Assigned to Universite de la Mediterranee, Marseilles (France); and Institut National de la Sante et de la Recherche Medicale, Paris (France)
Appl. No. 10/593,859 PCT Filed Mar. 30, 2005, PCT No. PCT/FR2005/000771 § 371(c)(1), (2), (4) Date Sep. 22, 2006, PCT Pub. No. WO2005/095594, PCT Pub. Date Oct. 13, 2005.
Prior Publication US 2007/0172485 A1, Jul. 26, 2007
Int. Cl. C07K 16/00 (2006.01)

U.S. Cl. 530—388.1  [424/130.1]

27 Claims

1. A monoclonal antibody selected from the group consisting of monoclonal antibody 16D10 or an antigen binding fragment thereof, having binding specificity for glycosylated bile salt dependent lipase (BSDL) or fetoacinar pancreatic protein (FAPP) and produced by the hybridoma deposited under the accession number I-3188; a monoclonal antibody, or an antigen binding fragment thereof, which binds to the same epitope of the BSDL or FAPP protein as monoclonal antibody 16D10; and a derivative of the 16D10 monoclonal antibody selected from the group consisting of a chimeric 16D10, humanized 16D10 or single chain scFv 16D10 antibody.